Tyra Biosciences, INC

Tyra Biosciences announced initial positive results from its Phase 2 SURF302 study of dabogratinib for bladder cancer, identifying a potential optimal dose and demonstrating clinical proof of concept.

Tyra Biosciences announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.

Tyra Biosciences announced first quarter 2026 financial results, highlighting progress in its dabogratinib clinical programs and a strong cash position extending runway into late 2028.

Tyra Biosciences has expanded its board of directors to ten members with the appointment of biopharmaceutical veteran Habib J. Dable.

Tyra Biosciences has designated Julia Rueb as its new principal accounting officer, effective April 1, 2026.

Tyra Biosciences, Inc. announced it will issue and sell 4 million shares of common stock to a large investment firm, expecting $126 million in gross proceeds.

Tyra Biosciences, Inc. announced its Q2 2026 financial results, highlighting increased research and development spending and a widening net loss, while also noting progress in its clinical pipeline and a strong cash position extending into late 2028.

Tyra Biosciences details Q1 2026 financial results, highlighting increased R&D spending and a strong cash position, while advancing its FGFR-targeted drug candidates.

Tyra Biosciences reported increased net losses and cash burn in Q3 2025, while advancing multiple clinical programs and maintaining a cash runway through at least 2027.

Tyra Biosciences reports increased R&D spend and net loss in Q2 2025, while maintaining a strong cash position to fund operations through at least 2027.

Tyra Biosciences reports a net loss for Q1 2025, but anticipates existing funds will support operations through at least 2027 as it progresses its clinical-stage programs.

Tyra Biosciences' Q3 2024 report highlights a strengthened financial position and advancements in clinical trials for its FGFR-targeted therapies.

TYRA Biosciences reports significant progress in its FGFR-targeted precision medicine pipeline, advancing three lead candidates into Phase 2 trials and detailing financial results for fiscal year 2025.

Tyra Biosciences details its financial performance for 2024 and highlights key advancements in its clinical-stage precision medicine programs.

Tyra Biosciences' 10-K filing highlights its clinical-stage progress in developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, with a focus on overcoming drug resistance.

Todd Harris, President and CEO and a Director of Tyra Biosciences, Inc., received 864 shares of common stock on September 15, 2026.

Yuliya Rueb, Vice President, Finance (PAO) of Tyra Biosciences, Inc., received 2,925 shares of common stock on September 15, 2026.

Alan Fuhrman, Chief Financial Officer of Tyra Biosciences, Inc., received 951 shares of common stock on September 15, 2026.

Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Tyra Biosciences, Inc. common stock on September 15, 2026.

Rehan Verjee, a Director of Tyra Biosciences, Inc., purchased 972 shares of common stock on September 9, 2026 for $20.58 per share.

RA Capital Management reports a stock option grant for director Dr. Jake Simson under the Tyra Biosciences non-employee director compensation program.

Tyra Biosciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026.

Tyra Biosciences will hold its annual stockholders meeting on May 29, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Tyra Biosciences announces its annual stockholders meeting to be held virtually on May 29, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Tyra Biosciences announces the appointment of two new independent directors, Susan Moran and S. Michael Rothenberg, along with updates to its Non-Employee Director Compensation Program.

Tyra Biosciences will hold its annual stockholders meeting on May 29, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and approve an amendment to the company's certificate of incorporation.

Tyra Biosciences will hold its annual stockholders meeting virtually on May 29, 2024, to vote on director elections, auditor ratification, and an amendment to the company's certificate of incorporation.

RA Capital Management and its affiliates reported a dilution of their beneficial ownership in TYRA Biosciences, now holding 21.2% of common stock.

RA Capital Healthcare Fund, L.P. has substantially increased its beneficial ownership in Tyra Biosciences, Inc. to 22.4% through a private stock purchase from Canaan XI L.P. and additional open market acquisitions.

RA Capital Management, L.P. and its affiliates have filed an Amendment No. 4 to their Schedule 13D, confirming their continued beneficial ownership of 20.1% of TYRA Biosciences, Inc.'s common stock.

Several Biotechnology Value Funds and Mark N. Lampert have filed a joint statement detailing their beneficial ownership of Tyra Biosciences, Inc. common stock.

Paradigm BioCapital Advisors LP, along with affiliated entities, has reported beneficial ownership of 5.8% of Tyra Biosciences, Inc. common stock as of September 10, 2026.

Nextech VI Oncology SCSp and related entities have reported beneficial ownership of 6.0% of Tyra Biosciences, Inc. common stock as of June 30, 2026.

Farallon Capital Management and affiliated entities have filed a Schedule 13G, reporting a passive ownership stake in Tyra Biosciences, Inc.

Commodore Capital LP and its principals have filed a Schedule 13G reporting a 4.2% beneficial ownership stake in Tyra Biosciences, Inc.

Janus Henderson Group plc has reported beneficial ownership of 3,890,589 shares, representing 7.2% of the common stock of Tyra Biosciences, Inc., as of March 31, 2026.